GLENMARK WEBSITES GLOBAL PRESENCE FOLLOW US | CONTACT US ABOUT US RESPONSIBILITY PRODUCTS INVESTORS CAREERS MEDIA Home > Investors > Latest Announcements Latest Announcements Glenmark Pharmaceuticals makes it to the prestigious Dow Jones Sustainability Emerging Markets Index for the fourth consecutive year 16 NOV 2021 | READ MORE Newspaper Publication of Q2 FY 2021-22 Result 15 NOV 2021 | READ MORE Glenmark Pharma reports revenue growth of 6.6% and PAT growth of 10.1% YoY for Q2 FY 2021-22 12 NOV 2021 | READ MORE Glenmark's MDA Q2 FY 2021 - 22 12 NOV 2021 | READ MORE Glenmark's Q2 FY 2021-22 Results 12 NOV 2021 | READ MORE Q2 FY22 Earnings Call Invitation - November 15, 2021 3 NOV 2021 | READ MORE Board Meeting Intimation - 12 November, 2021 1 NOV 2021 | READ MORE Glenmark becomes the first company to launch Remogliflozin + Vildagliptin + Metformin fixed dose combination, at an affordable price for adults with Type 2 Diabetes in India 26 OCT 2021 | READ MORE Glenmark launches Tavulus® for COPD treatment in Spain, becoming one of the first companies to launch a bioequivalent version of the dry powder inhaler 11 OCT 2021 | READ MORE Chairman's Speech at 43rd AGM 6 OCT 2021 | READ MORE Transcript of the 43rd AGM 6 OCT 2021 | READ MORE Proceedings and Scrutinizer's Report of the 43rd AGM 6 OCT 2021 | READ MORE Glenmark receives marketing approval for Ryaltris®, an innovative combination nasal spray, in 13 countries across the EU and UK 30 SEP 2021 | READ MORE Glenmark Pharmaceuticals receives ANDA approval for Clindamycin Phosphate Foam, 1% 21 SEP 2021 | READ MORE Glenmark concludes post marketing surveillance (PMS) study on Favipiravir (FabiFlu®) in 1000+ COVID-19 patients, findings reinforce the drug’s safety and efficacy in real world settings 15 SEP 2021 | READ MORE 43rd AGM Notice - Newspaper Advertisement 8 SEP 2021 | READ MORE Glenmark AGM Notice 2021 27 AUG 2021 | READ MORE Newspaper Publication of Q1 FY 2021-22 Result 16 AUG 2021 | READ MORE Glenmark Pharma reports revenue growth of 26% and PAT growth of 21% YoY for Q1 FY 2021-22 13 AUG 2021 | READ MORE Glenmark’s MDA Q1 FY 2021 – 22 13 AUG 2021 | READ MORE Glenmark’s Q1 FY 2021-22 Results 13 AUG 2022 | READ MORE Q1 FY22 Earnings Call Invitation – August 16, 2021 9 AUG 2021 | READ MORE Board Meeting Intimation – 13th August, 2021 6 AUG 2021 | READ MORE Glenmark inks agreement with Canadian biotech SaNOtize to commercialize Nitric Oxide Nasal Spray for COVID-19 treatment in India and other Asian markets 2 AUG 2021 | READ MORE Newspaper notice to shareholders for transfer of shares to IEPF 28 JUN 2021 | READ MORE SCRIP_27 May 2021: Favipiravir Adds Near-Equivalent Of AZ India To Glenmark's Sales 28 JUN 2021 | READ MORE Glenmark receives ANDA tentative approval for Nintedanib Capsules, 100 mg and 150 mg 25 JUN 2021 | READ MORE Glenmark Pharmaceuticals receives ANDA approval for Arformoterol Tartrate Inhalation Solution, 15 mcg/2 mL, Unit-Dose Vials 23 JUN 2021 | READ MORE Glenmark launches Tiogiva®, becoming one of the first companies in the UK to launch a bioequivalent version of Tiotropium Bromide dry powder inhaler 15 JUN 2021 | READ MORE Glenmark releases interim data from PMS Study on Favipiravir 8 JUN 2021 | READ MORE Glenmark Pharmaceuticals receives ANDA approval for Theophylline Extended-Release Tablets, 300 mg and 450 mg: Granted competitive generic therapy (CGT) designation and is eligible for 180 days of CGT exclusivity on the 450 mg 4 JUN 2021 | READ MORE Glenmark Pharmaceuticals launches Rufinamide Tablets USP, 200 mg and 400 mg 1 JUN 2021 | READ MORE Newspaper Publication of Q4 FY 2020-21 Result 31 MAY 2021 | READ MORE Glenmark’s consolidated revenues grow 2.8% to Rs. 1,09,439 Mn in FY21 28 MAY 2021 | READ MORE Glenmark’s MDA Q4 FY 2020 – 21 28 MAY 2021 | READ MORE Glenmark’s Q4 FY 2020-21 Results 28 MAY 2021 | READ MORE Glenmark Pharmaceuticals receives ANDA approval for Icatibant Injection, 30 mg/3 mL (10 mg/mL) Single-Dose Prefilled Syringe 24 MAY 2021 | READ MORE Newspaper Advertisement for the Board Meeting on 28th May, 2021 20 MAY 2021 | READ MORE Q4 FY21 Earnings Call Invitation – May 31, 2021 20 MAY 2021 | READ MORE Board Meeting Intimation – 28th May, 2021 19 MAY 2021 | READ MORE Glenmark launches Ryaltris®-AZ at an affordable price in India 3 MAY 2021 | READ MORE Glenmark Pharmaceuticals Limited has entered into an agreement to become a partner in ABCD Technologies LLP (to be renamed as Indo Health Services LLP) 30 APR 2021 | READ MORE Glenmark’s Ryaltris ® nasal spray now approved in Europe for the first line treatment of allergic rhinitis in patients over 12 years of age 26 APR 2021 | READ MORE Proposed Initial Public Offering (“IPO”) of Glenmark Life Sciences Limited‐ Filing of draft red herring prospectus 17 APR 2021 | READ MORE Glenmark Pharmaceuticals receives ANDA approval for Chlorpromazine Hydrochloride Tablets USP, 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg: Granted competitive generic therapy (CGT) designation and is eligible for 180 days of CGT exclusivity. 24 MAR 2021 | READ MORE Glenmark Pharmaceuticals receives ANDA approval for Diltiazem Hydrochloride Extended-Release Capsules USP, 60 mg, 90 mg, and 120 mg: Granted competitive generic therapy (CGT) designation and is eligible for 180 days of CGT exclusivity 23 MAR 2021 | READ MORE Glenmark and Bausch Health join together to commercialize RYALTRIS ™ nasal spray in Canada 22 MAR 2021 | READ MORE Glenmark signs on Rohit Sharma as brand ambassador of Candid Powder 5 MAR 2021 | READ MORE Glenmark receives ‘India Pharma Innovation of the Year’ Award from the Govt. of India 25 FEB 2021 | READ MORE Glenmark’s Ryaltris®- innovative single nasal spray, ready to market in Russia 22 FEB 2021 | READ MORE Newspaper Publication of Q3 FY 2020-21 Result 16 FEB 2021 | READ MORE Glenmark launches SUTIB (Sunitinib) – priced 96% lower than the innovator brand. Reduces the risk of kidney cancer progression by 58% 16 FEB 2021 | READ MORE Glenmark’s consolidated sales rises by 3.88% to Rs. 27,605.07 Mn. in Q3 FY 2020-21 12 FEB 2021 | READ MORE Glenmark’s MDA Q3 FY 2020 – 21 12 FEB 2021 | READ MORE Glenmark’s Q3 FY 2020-21 Results 12 FEB 2021 | READ MORE Glenmark Pharmaceuticals receives ANDA approval for Clindamycin Phosphate Gel USP, 1% 11 FEB 2021 | READ MORE Glenmark Pharmaceuticals receives ANDA approval for Topiramate Extended-Release Capsules, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg 3 FEB 2021 | READ MORE Newspaper Advertisement for the Board Meeting on 12th February, 2021 2 FEB 2021 | READ MORE Board Meeting Intimation – 12th February, 2021 1 FEB 2021 | READ MORE Q3 FY21 Earnings Call Invitation – February 15, 2021 1 FEB 2021 | READ MORE Glenmark Pharmaceuticals receives ANDA approval for Amphetamine Sulfate Tablets USP, 5 mg and 10 mg 28 JAN 2021 | READ MORE Glenmark Pharmaceuticals receives ANDA final approval for Tadalafil Tablets, 2.5 mg, 5 mg, 10 mg and 20 mg; and receives ANDA tentative approvals for Gabapentin Enacarbil Extended-Release Tablets, 300 mg and 600 mg and Apremilast Tablets, 10 mg, 20 mg and 31 DEC 2020 | READ MORE Glenmark becomes the first company to launch Remogliflozin + Vildagliptin fixed dose combination, at an affordable price for adults with Type 2 Diabetes in India 29 DEC 2020 | READ MORE Glenmark Pharmaceuticals and Menarini enter into Exclusive Licensing Agreement for commercializing Ryaltris™ Nasal Spray across numerous markets throughout Europe. 23 DEC 2020 | READ MORE Glenmark Pharmaceuticals receives ANDA tentative approval for Dabigatran Etexilate Capsules, 75 mg, 110 mg, and 150 mg 21 DEC 2020 | READ MORE Glenmark Pharmaceuticals receives ANDA tentative approval for Axitinib Tablets,1 mg and 5 mg 1 DEC 2020 | READ MORE Glenmark to divest select Anti-Allergy brands to Dr Reddy’s in Russia, Ukraine, Kazakhstan and Uzbekistan in anticipation of its ‘Ryaltris’ Launch 28 NOV 2020 | READ MORE Credit Rating by S&P Global Ratings 25 NOV 2020 | READ MORE Recently published data on Favipiravir as treatment for mild to moderate COVID-19 demonstrates significant improvement in time to clinical cure 23 NOV 2020 | READ MORE Glenmark Pharmaceuticals receives ANDA approval for Tacrolimus Capsules USP, 0.5 mg, 1 mg and 5 mg 11 NOV 2020 | READ MORE Newspaper Publication of Q2 FY 2020-21 Result 9 NOV 2020 | READ MORE Glenmark’s consolidated revenue increased by 4.88 % to Rs. 29,524.79 mn for Q2 FY 2020-21 6 NOV 2020 | READ MORE Glenmark’s MDA Q2 FY 2020 – 21 6 NOV 2020 | READ MORE Glenmark’s Q2 FY 2020-21 Results 6 NOV 2020 | READ MORE Board Meeting Newspaper Advertisement – November 6, 2020 29 OCT 2020 | READ MORE Q2 FY21 Earnings Call Invitation – November 9, 2020 28 OCT 2020 | READ MORE Board Meeting Intimation – 6th November, 2020 27 OCT 2020 | READ MORE Glenmark Pharmaceuticals receives ANDA approval for Sirolimus Tablets, 0.5 mg, 1 mg and 2 mg 19 OCT 2020 | READ MORE Glenmark introduces NINDANIB (Nintedanib) for the treatment of Pulmonary Fibrosis in India 14 OCT 2020 | READ MORE Glenmark announces results of its “FAITH” combination trial 14 OCT 2020 | READ MORE Transcript of the 42nd AGM 5 OCT 2020 | READ MORE Proceedings and Scrutinizer's Report of the 42nd AGM 30 SEP 2020 | READ MORE Chairman’s Speech at the 42nd AGM 30 SEP 2020 | READ MORE 42nd AGM Notice – Newspaper Advertisement 7 SEP 2020 | READ MORE Newspaper Advertisement of 42nd Annual General Meeting 4 SEP 2020 | READ MORE Glenmark AGM Notice 2020 4 SEP 2020 | READ MORE Newspaper Publication of Q1 FY 2020-21 Result 17 AUG 2020 | READ MORE Glenmark’s consolidated revenue grew by 0.94 % at Rs. 23,447.87 Mn. for Q1 FY 2020-21 14 AUG 2020 | READ MORE Glenmark’s MDA Q1 FY 2020 – 21 14 AUG 2020 | READ MORE Glenmark’s Q1 FY 2020-21 Results 14 AUG 2020 | READ MORE Board Meeting Newspaper Advertisement – 14th August, 2020 7 AUG 2020 | READ MORE Board Meeting Intimation – 14th August, 2020 6 AUG 2020 | READ MORE Q1 FY21 Earnings Call Invitation – August 17, 2020 6 AUG 2020 | READ MORE Credit Rating by Fitch Ratings 13 JUL 2020 | READ MORE Notice to Shareholders for transfer of shares to IEPF 2 JUL 2020 | READ MORE Glenmark’s consolidated revenue rises 7.96% to Rs. 27,674.89 Mn. for Q4 FY2019-20 26 JUN 2020 | READ MORE Glenmark’s MDA Q4 FY 2019 – 20 26 JUN 2020 | READ MORE Glenmark’s Q4 FY 2019-20 Results 26 JUN 2020 | READ MORE Board Meeting Intimation – 26th June, 2020 19 JUN 2020 | READ MORE Board Meeting Intimation – 26th June, 2020 17 JUN 2020 | READ MORE Q4 FY20 Earnings Call Invitation – June 29, 2020 17 JUN 2020 | READ MORE Glenmark initiates Phase 3 clinical trials on antiviral Favipiravir for COVID-19 patients in India 12 MAY 2020 | READ MORE Glenmark introduces 3-in-1 inhaler therapy for COPD in India, promising reduction in risk of severe attacks and improvement in lung function 11 MAY 2020 | READ MORE Glenmark receives approval from the regulator (DCGI) to conduct Clinical Trials in India on Favipiravir Antiviral tablets for COVID-19 patients 30 APR 2020 | READ MORE Glenmark Pharmaceuticals receives ANDA tentative approval for Dapagliflozin and Saxagliptin Tablets, 10 mg/5 mg 29 APR 2020 | READ MORE Glenmark Pharmaceuticals receives ANDA tentative approval for Dapagliflozin Tablets, 5 mg and 10 mg 23 MAR 2020 | READ MORE Glenmark divests VWash, a female intimate hygiene wash, to Hindustan Unilever 23 MAR 2020 | READ MORE Glenmark Pharmaceuticals and Hikma enter into an Exclusive Licensing Agreement for commercializing Ryaltris™ Seasonal Allergic Rhinitis Nasal Spray in the US 27 FEB 2020 | READ MORE Newspaper Publication of Q3 FY 2019-20 Result 17 FEB 2020 | READ MORE Glenmark’s consolidated revenue rises by 7.07% to Rs. 27,355.61 Mn. in Q3 FY 2019-20 14 FEB 2020 | READ MORE Glenmark’s MDA Q3 FY 2019 – 20 14 FEB 2020 | READ MORE Glenmark’s Q3 FY 2019-20 Results 14 FEB 2020 | READ MORE Q3 FY20 Earnings Call Invitation – February 17, 2020 4 FEB 2020 | READ MORE BM Notice Newspaper Publication – 14th February, 2020 3 FEB 2020 | READ MORE Notice of Board Meeting - 31st January, 2020 31 JAN 2020 | READ MORE Glenmark Pharmaceuticals announces product approval for Ryaltris(R) in Australia 20 DEC 2019 | READ MORE Certificate of Compliance issued by the European regulator, SUKL, Czech Republic for Glenmark’s Baddi manufacturing facility 16 DEC 2019 | READ MORE Newspaper Publication of Q2 FY 2019-20 19 NOV 2019 | READ MORE Glenmark’s consolidated revenue rises 9.05% to Rs. 28,150.4 Mn. in Q2 FY 2019-20 14 NOV 2019 | READ MORE Glenmark’s MDA Q2 FY 2019 – 20 14 NOV 2019 | READ MORE Glenmark’s Q2 FY 2019-20 Results 14 NOV 2019 | READ MORE Glenmark Pharmaceuticals receives ANDA approval for Adapalene and Benzoyl Peroxide Gel, 0.1%|2.5% 11 NOV 2019 | READ MORE Q2 FY20 Earnings Concall Invitation - November 15, 2019 7 NOV 2019 | READ MORE BM Notice Newspaper Publication – 14th November, 2019 6 NOV 2019 | READ MORE Notice of Board Meeting - 14th November, 2019 5 NOV 2019 | READ MORE Proceedings and Scrutinizer's Report of the 41st AGM 28 SEP 2020 | READ MORE Newspaper Publication of Annual General Meeting Notice 5 SEP 2019 | READ MORE Glenmark AGM Notice 2019 3 SEP 2019 | READ MORE AGM Intimation to the Exchange 25 AUG 2019 | READ MORE Glenmark Pharmaceuticals receives ANDA approval for Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) 23 AUG 2019 | READ MORE Glenmark’s consolidated revenue at Rs. 23,228.79 Mn. for Q1 FY 2019 – 20 13 AUG 2019 | READ MORE Glenmark’s MDA Q1 FY 2019 – 20 13 AUG 2019 | READ MORE Glenmark’s Q1 FY 2019-20 Results 13 AUG 2019 | READ MORE Glenmark Q1 FY 2019 – 20 Results Earnings Call 5 AUG 2019 | READ MORE BM Notice Newspaper Publication – 13th August, 2019 1 AUG 2019 | READ MORE Notice of Board Meeting - 13th August, 2019 31 JUL 2019 | READ MORE Credit Rating by Fitch Ratings 11 JUL 2019 | READ MORE Newspaper Publication - Notice to Shareholder for transfer of shares to IEPF 26 JUN 2019 | READ MORE FDA Issues Complete Response Letter for Ryaltris™ (olopatadine hydrochloride [665 mcg] and mometasone furoate [25 mcg]) 22 JUN 2019 | READ MORE Newspaper Publication of Q4 Results 31 MAY 2019 | READ MORE Glenmark’s Q4 FY 2018-19 Results 29 MAY 2019 | READ MORE Glenmark’s consolidated revenue rises 12.44% to Rs. 25,634.74 Mn. for Q4 FY 2018-19 29 MAY 2019 | READ MORE Glenmark’s MDA Q4 FY 2018 – 19 29 MAY 2019 | READ MORE BM Notice Newspaper Publication – 29th May, 2019 22 MAY 2019 | READ MORE Glenmark Q4 FY 2018 - 19 Results Earnings Call 21 MAY 2019 | READ MORE Board Meeting Intimation – 29th May, 2019 14 MAY 2019 | READ MORE Newspaper Publication of Q3 Results 18 FEB 2019 | READ MORE Glenmark’s consolidated revenue rises 15.95% to Rs. 25,550.45 Mn. in Q3 FY 2018 – 19 14 FEB 2019 | READ MORE Glenmark’s MDA Q3 FY 2018 – 19 14 FEB 2019 | READ MORE Glenmark’s Q3 FY 2018-19 Results 14 FEB 2019 | READ MORE BM Newspaper Publication – 14th February, 2019 4 FEB 2019 | READ MORE Glenmark Q3 FY 2018 - 19 Results Earnings Call 4 FEB 2019 | READ MORE Board Meeting Intimation – 14th February, 2019 1 FEB 2019 | READ MORE J P Morgan Healthcare Conference 2019 I Presentation 8 JAN 2019 | READ MORE Newspaper Publication of Q2 Results 23 NOV 2018 | READ MORE Glenmark’s MDA Q2 FY 2018 – 19 13 NOV 2018 | READ MORE Glenmark’s Q2 FY 2018-19 Results 13 NOV 2018 | READ MORE Glenmark’s consolidated revenue rises 14.39% to Rs. 25,813.32 Mn. in Q2 FY 2018 – 19 13 NOV 2018 | READ MORE BM Newspaper Publication 5 NOV 2018 | READ MORE Board Meeting Notice November 13, 2018 2 NOV 2018 | READ MORE Announcement of Results of the Repurchase 3 OCT 2018 | READ MORE Newspaper Publication of Annual General Meeting Notice 28 SEP 2018 | READ MORE AGM Intimation to the exchange 21 AUG 2018 | READ MORE Newspaper Publication of Q1 Results 19 AUG 2018 | READ MORE Glenmark’s consolidated revenue at Rs. 21,656.17 Mn. for Q1 FY 2018 – 19 10 AUG 2018 | READ MORE Glenmark’s Q1 FY 2018-19 Results 10 AUG 2018 | READ MORE Glenmark’s MDA Q1 FY 2018 – 19 10 AUG 2018 | READ MORE Q1 FY19 Earnings Concall Invitation - Aug 13, 2018 3 AUG 2018 | READ MORE Glenmark BM Notice Navshakti 31 JUL 2018 | READ MORE Glenmark BM Notice FPJ 31 JUL 2018 | READ MORE IEPF – Notice to Shareholders 29 JUN 2018 | READ MORE Newspaper Publication of Q4/Annual Results - Loksatta 6 JUN 2018 | READ MORE Newspaper Publication of Q4/Annual Results 5 JUN 2018 | READ MORE Glenmark’s consolidated revenue at Rs. 22,798.16 Mn. for Q4 FY 2017 – 18 29 MAY 2018 | READ MORE Glenmark’s MDA Q4 FY 18 29 MAY 2018 | READ MORE Glenmark’s Q4 FY18 Results 29 MAY 2018 | READ MORE Q4 Earnings Concall Invitation 28 MAY 2018 | READ MORE Glenmark BM Notice Navshakti 17 MAY 2018 | READ MORE Glenmark BM Notice FPJ 17 MAY 2018 | READ MORE Newspaper Publication of Q3 Results 9 FEB 2018 | READ MORE AGM Notice Announcement 8 SEP 2017 | READ MORE Board Meeting Notice July 27, 2017 14 JUL 2017 | READ MORE Glenmark FPJ Page 10 14 JUL 2017 | READ MORE Glenmark Navshakti Page 8 14 JUL 2017 | READ MORE Glenmark Pharmaceuticals Receives Tentative ANDA Approval For Solifenacin Succinate Tablets, 5 mg and 10 mg 22 JUN 2017 | READ MORE Glenmark's consolidated revenue increased by 6.52% to Rs. 24,571.83 Mn for Q4 FY 2016 -- 17 11 MAY 2017 | READ MORE Q4 FY 2017 Results sheet & Statement of Assets and Liabilities 11 MAY 2017 | READ MORE Q4 FY 2017 Management Discussions and Analysis 11 MAY 2017 | READ MORE Q4 Earnings Concall Invitation May 12, 2017 8 MAY 2017 | READ MORE The Free Press Journal 5 MAY 2017 | READ MORE Navshakti 5 MAY 2017 | READ MORE Intimation regarding NSE board meeting 3 MAY 2017 | READ MORE Statement on Form 483 at the Ankleshwar API plant 20 FEB 2017 | READ MORE Glenmark’s Q3 FY 17 results 2 FEB 2017 | READ MORE Glenmark’s MDA Q3 FY 17 2 FEB 2017 | READ MORE Glenmark’s consolidated revenue increases by 42.55 % to Rs. 25,350.08 Mn for Q3 FY 2016 – 17 2 FEB 2017 | READ MORE J P Morgan Healthcare Conference – presentation 30 JAN 2017 | READ MORE Intimation regarding board meeting 17 JAN 2017 | READ MORE Statement of Investor Complaints for Q3 (F. Y. 2016-17) 11 JAN 2016 | READ MORE Webcast of analyst and investor meet 2016 29 DEC 2016 | READ MORE Strategic Blueprint for the Next Decade – Investor presentation 19 DEC 2016 | READ MORE Strategic Blueprint for the Next Decade – Media presentation 19 DEC 2016 | READ MORE Glenmark's Q2 FY17 Result Balance Sheet 2 NOV 2016 | READ MORE Glenmark's MDA Q2 FY 2017 2 NOV 2016 | READ MORE Glenmark’s consolidated revenue increases by 16.48% to Rs. 22241.09 Mn for Q2 FY 2016 – 17 2 NOV 2016 | READ MORE Statement of Investor Complaints for Q2 10 OCT 2016 | READ MORE Shareholding Pattern for Q2 10 OCT 2016 | READ MORE Corporate Governance Report for Q2 10 OCT 2016 | READ MORE Reconciliation of Share Capital Audit Report 10 OCT 2016 | READ MORE Compliance Certificate under Regulation 7(3) 10 OCT 2016 | READ MORE Certificate from Practicing Company Secretary under Regulation 40(9) 10 OCT 2016 | READ MORE 38th AGM Proceedings 12 AUG 2016 | READ MORE 38th AGM Notice – The Free Press Journal 21 JUL 2016 | READ MORE 38th AGM Notice – Navshakti 21 JUL 2016 | READ MORE Glenmark e-voting notice 19 JUL 2016 | READ MORE Glenmark notice proxy form 19 JUL 2016 | READ MORE Annual report FY 2016 19 JUL 2016 | READ MORE Intimation to the exchange 18 JUL 2016 | READ MORE Statement of Investor Complaint 13 JUL 2016 | READ MORE Reconciliation Share Capital 30 JUN 2016 | READ MORE Q4 Shareholding Pattern 30 JUN 2016 | READ MORE Corporate governance website 30 JUN 2016 | READ MORE Approval of Subscription Agreement for FCCB's 31 MAY 2016 | READ MORE Launch of FCCB's 31 MAY 2016 | READ MORE Q4 - Statement of Investor Complaints 7 APR 2016 | READ MORE Q4 - Reconciliation Share Capital 31 MAR 2016 | READ MORE Q4 - Format of Holding of specified securities (2) 31 MAR 2016 | READ MORE Q4 - Format of Holding of specified securities 31 MAR 2016 | READ MORE Authorised KMP for Disclosure of Materality of Events or Information 28 JAN 2016 | READ MORE Cancellations of ESOP Options 28 JAN 2016 | READ MORE Glenmark JPMorgan 2016 15 JAN 2016 | READ MORE GOVERNANCE The principles that govern us KNOW MORE SHAREHOLDERS CORNER Be a part of the new world KNOW MORE REPORTS AND PRESENTATION Performance in numbers KNOW MORE About Us Leading, integrated, global, research-led organization. Words which define us and our vision to discover a healthier future KNOW MORE TERMS OF USE ABOUT US RESPONSIBILITY PRODUCTS INVESTORS CAREERS MEDIA COPYRIGHT© 2021, ALL RIGHTS RESERVED